Sara Arjona-Hernandez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sara Arjona-Hernandez has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Alberto Manuel Borobia
Clinical Pharmacology Department, La Paz University Hospital-IdiPAZ, School of Medicine, Autonomous University of Madrid, 28046 Madrid, Spain
1 shared publication - Carlos Rodríguez-Antolín
Instituto de Genética Médica y Molecular, Instituto de Investigación Sanitaria del Hospital Universitario La Paz, Madrid, Madrid, Spain
1 shared publication - Inmaculada Ibanez de Caceres
Cancer Epigenetics Laboratory, INGEMM, La Paz University Hospital, Madrid, Spain
1 shared publication - Itsaso Losantos-García
Biostatistics Department, La Paz University Hospital, IdiPAZ, Paseo de la Castellana 261, 28046 Madrid, Spain
1 shared publication - Javier Guijarro-Eguinoa
Clinical Pharmacology Department, La Paz University Hospital, 28046 Madrid, Spain
1 shared publication - Javier de Castro
Hospital Universitario La Paz, Madrid, Spain
1 shared publication
Latest Publications
- Open Access
- 7 June 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (12) , 9843
Prognostic Impact of Dihydropyrimidine Dehydrogenase Germline Variants in Unresectable Non-Small Cell Lung Cancer Patients Treated with Platin-Based Chemotherapy
Platin-based chemotherapy is the standard treatment for patients with non-small cell lung cancer (NSCLC). However, resistance to this therapy is a major obstacle in successful treatment. In this study, we aimed to investigate the impact of several pharmacogenetic variants in patients with unresectable NSCLC treated with platin-based chemotherapy. Our results showed that DPYD variant carriers had significantly shorter progression-free survival and overall survival compared to DPYD wild-type patients, whereas DPD deficiency was not associated with a higher incidence of high-grade toxicity. For the first time, our study provides evidence that DPYD gene variants are associated with resistance to platin-based chemotherapy in NSCLC patients. Although further studies are needed to confirm these findings and explore the underlying mechanisms of this association, our results suggest that genetic testing of DPYD variants may be useful for identifying patients at a higher risk of platin-based chemotherapy resistance and might be helpful in guiding future personalized treatment strategies in NSCLC patients.
- 7 June 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (12) , 9843
Open AccessPrognostic Impact of Dihydropyrimidine Dehydrogenase Germline Variants in Unresectable Non-Small Cell Lung Cancer Patients Treated with Platin-Based Chemotherapy
Platin-based chemotherapy is the standard treatment for patients with non-small cell lung cancer (NSCLC). However, resistance to this therapy is a major obstacle in successful treatment. In this study, we aimed to investigate the impact of several pharmacogenetic variants in patients with unresectable NSCLC treated with platin-based chemotherapy. Our results showed that DPYD variant carriers had significantly shorter progression-free survival and overall survival compared to DPYD wild-type patients, whereas DPD deficiency was not associated with a higher incidence of high-grade toxicity. For the first time, our study provides evidence that DPYD gene variants are associated with resistance to platin-based chemotherapy in NSCLC patients. Although further studies are needed to confirm these findings and explore the underlying mechanisms of this association, our results suggest that genetic testing of DPYD variants may be useful for identifying patients at a higher risk of platin-based chemotherapy resistance and might be helpful in guiding future personalized treatment strategies in NSCLC patients.